CN103585190A - Application of Theloschestes flavicans extract in preparation of anti-liver cancer drugs - Google Patents
Application of Theloschestes flavicans extract in preparation of anti-liver cancer drugs Download PDFInfo
- Publication number
- CN103585190A CN103585190A CN201310525674.9A CN201310525674A CN103585190A CN 103585190 A CN103585190 A CN 103585190A CN 201310525674 A CN201310525674 A CN 201310525674A CN 103585190 A CN103585190 A CN 103585190A
- Authority
- CN
- China
- Prior art keywords
- wall tapestry
- extract
- tapestry extract
- wall
- extraction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000284 extract Substances 0.000 title claims abstract description 137
- 208000014018 liver neoplasm Diseases 0.000 title claims abstract description 25
- 201000007270 liver cancer Diseases 0.000 title claims abstract description 24
- 238000002360 preparation method Methods 0.000 title claims abstract description 20
- 239000003560 cancer drug Substances 0.000 title abstract 3
- 239000011347 resin Substances 0.000 claims abstract description 19
- 229920005989 resin Polymers 0.000 claims abstract description 19
- 239000000341 volatile oil Substances 0.000 claims abstract description 19
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 57
- 238000000605 extraction Methods 0.000 claims description 55
- 239000003814 drug Substances 0.000 claims description 38
- 229940079593 drug Drugs 0.000 claims description 28
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 19
- 239000002904 solvent Substances 0.000 claims description 18
- 238000010438 heat treatment Methods 0.000 claims description 10
- 230000000274 adsorptive effect Effects 0.000 claims description 9
- 230000001476 alcoholic effect Effects 0.000 claims description 9
- 239000006286 aqueous extract Substances 0.000 claims description 9
- 239000012141 concentrate Substances 0.000 claims description 9
- 238000001035 drying Methods 0.000 claims description 9
- 239000003480 eluent Substances 0.000 claims description 9
- 238000010992 reflux Methods 0.000 claims description 9
- 238000001256 steam distillation Methods 0.000 claims description 9
- 239000003463 adsorbent Substances 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 7
- 239000008187 granular material Substances 0.000 claims description 6
- 239000000126 substance Substances 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 4
- 239000002671 adjuvant Substances 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims description 2
- 238000000746 purification Methods 0.000 abstract description 2
- 239000002994 raw material Substances 0.000 abstract description 2
- 238000001179 sorption measurement Methods 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 25
- 206010028980 Neoplasm Diseases 0.000 description 18
- 201000011510 cancer Diseases 0.000 description 7
- WFWLQNSHRPWKFK-ZCFIWIBFSA-N tegafur Chemical compound O=C1NC(=O)C(F)=CN1[C@@H]1OCCC1 WFWLQNSHRPWKFK-ZCFIWIBFSA-N 0.000 description 7
- 238000011282 treatment Methods 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 230000014509 gene expression Effects 0.000 description 5
- 210000002540 macrophage Anatomy 0.000 description 5
- 231100000614 poison Toxicity 0.000 description 5
- 239000002574 poison Substances 0.000 description 5
- 229960001674 tegafur Drugs 0.000 description 5
- 241000196324 Embryophyta Species 0.000 description 4
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 208000037920 primary disease Diseases 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000001959 radiotherapy Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000001644 anti-hepatocarcinoma Effects 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000008451 emotion Effects 0.000 description 2
- 208000002672 hepatitis B Diseases 0.000 description 2
- 235000008216 herbs Nutrition 0.000 description 2
- 238000011532 immunohistochemical staining Methods 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 230000005180 public health Effects 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 229930195730 Aflatoxin Natural products 0.000 description 1
- XWIYFDMXXLINPU-UHFFFAOYSA-N Aflatoxin G Chemical compound O=C1OCCC2=C1C(=O)OC1=C2C(OC)=CC2=C1C1C=COC1O2 XWIYFDMXXLINPU-UHFFFAOYSA-N 0.000 description 1
- 241000202726 Bupleurum Species 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 206010073069 Hepatic cancer Diseases 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 108010042653 IgA receptor Proteins 0.000 description 1
- 206010061245 Internal injury Diseases 0.000 description 1
- 206010027336 Menstruation delayed Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102100034014 Prolyl 3-hydroxylase 3 Human genes 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 239000005409 aflatoxin Substances 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 208000006990 cholangiocarcinoma Diseases 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical class OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000005202 decontamination Methods 0.000 description 1
- 230000003588 decontaminative effect Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- -1 dry Substances 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 239000009519 fu-yuan Substances 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000012151 immunohistochemical method Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 201000007450 intrahepatic cholangiocarcinoma Diseases 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000000505 pernicious effect Effects 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses new application of a Theloschestes flavicans extract in preparation of anti-liver cancer drugs. The Theloschestes flavicans extract is prepared by: taking Theloschestes flavicans as a raw material, extracting volatile oil, conducting macroporous adsorption resin purification to obtain a Theloschestes flavicans extract A, a Theloschestes flavicans extract B and a Theloschestes flavicans extract C, and mixing them in certain proportion. The Theloschestes flavicans extract provided by the invention is of great significance in preparing anti-liver cancer drugs.
Description
Technical field
The invention belongs to biomedicine field, relate to the application of a kind of Chinese crude drug extract in preparing medicines resistant to liver cancer, specifically relate to the application of wall tapestry extract in preparing medicines resistant to liver cancer.
Background technology
According in February, 2010 Ministry of Public Health statistics, annual global cancer mortality number reaches 1,000 ten thousand.At present the whole world 1/4th human mortalities' reason is due to cancer, and prediction goes down by current trend development, to the year two thousand fifty by the died that has 1/2nd, be owing to having suffered from cancer.The pernicious cancer morbidity of China, with annual 2.5-5% speed increment, has become serious harm human life's arch-criminal.Higher with sickness rate such as hepatocarcinoma in the middle of various types of cancers.
Hepatocarcinoma refers to the malignant tumor that betides liver, comprises two kinds of primary hepatocarcinoma and secondary liver cancers, and mostly the hepatocarcinoma of the daily theory of people is primary hepatocarcinoma if referring to.Primary hepatocarcinoma is one of modal malignant tumor clinically, and according to recent statistics, the annual new liver cancer patient approximately 600,000 in the whole world, occupies the 5th of malignant tumor.Primary hepatocarcinoma can be divided into Hepatocellular carcinoma, intrahepatic cholangiocarcinoma and mixed carcinoma of liver by cell typing.By the form of tumor, can be divided into nodular type, massive type and diffuse type.Primary hepatocarcinoma belongs to high morbidity in China, and general male is more than women.China is hepatitis B big country, and how the hepatocarcinoma of China develops on the basis of hbv-liver cirrhosis, and hepatitis C patient also, increasing gradually, also can develop into hepatocarcinoma after hepatitis B.China's number of the infected accounts for the more than half of the whole world at present, accounts for 55% of global hepatocarcinoma patient, has become a large killer of serious threat China people health and lives, and its danger can not look down upon.Hepatocarcinoma can betide any age, but take 31～50 years old as many, and men and women's ratio is about 8:1.In more than 90% belonging to when making a definite diagnosis, late period, surgical engine can many miss, so adopt modern comprehensive treatment often because Radiotherapy chemotherapy and immunization therapy are subject to certain limitation; And Radiotherapy chemotherapy is very big to the treatment toxicity of primary disease, indication reduces, and curative effect is also poor; Though interventional therapy has certain curative effect, need quite high condition and equipment, spend also larger.Therefore Chinese medicine has become one of primary treatment means of primary disease.Chinese medicine also with Radiotherapy chemotherapy fit applications, can play preferably " attenuation synergistic " effect.
The cause of disease of the treatment by Chinese herbs hepatocarcinoma of hepatocarcinoma, it is relevant with chronic hepatic diseases, aflatoxin, parasite, excessive drinking, inherited genetic factors that doctor trained in Western medicine is thought mainly.In China, be related to that with onset of liver cancer rate the factor of maximum is hepatitis B virus, particularly HBsAg positive.Therefore, HBsAg positive and chronic hepatitis patients are listed in the high-risk group of hepatocarcinoma.Have research to think, HBsAg has directly carcinogenic possibility, and not necessarily by this interstage of chronic hepatopathy.
The traditional Chinese medical science thinks that primary disease is mainly lost by internal organs asthenia of qi and blood, insufficiency of the spleen wet poly-, the expectorant blood coagulation stasis of blood; The evil poison invasion of six climate exopathogens, evil solidifying poison knot, internal injury caused by excess of seven emotions, depressed emotions etc., can make gas, blood, wet, heat, the stasis of blood, poison tie and form hepatocarcinoma mutually.Primary disease disease located in liver, closely related with spleen, gallbladder, stomach, main pathogenesis is weakened body resistance in interior, evil poison pents up.In treatment, by determination for the treatment of based on pathogenesis obtained through differentiation of symptoms and signs, main minute following four types: the treatment by Chinese herbs depression of liver-QI of hepatocarcinoma, square medicine is selected bupleurum powder for relieving liver-qi plus-minus; Qi depression to blood stasis, selects Fuyuan Huoxue Tangization to cut out; Damp and hot poly-poison, Herba Artemisiae Scopariae Decoction plus-minus; Deficiency and exhaustion of liver-YIN, square medicine is selected YIGUANJIAN to close xijiao Dihuang Tangization and is cut out.
Wall tapestry is the dry thallus of lichens Teloshistaceae plant wall tapestry Theloschestes flavicans (Sw.) Norm.After collection, remove earth, dry.Record in < < Drug Standard of Ministry of Public Health of the Peoples Republic of China Tibetan medicine (first) > >, standard number: WS3-BC-0125-95.Cool in nature, bitter in the mouth.There is heat extraction, the effect of removing toxic substances.For lung-heat, liver-heat, arteries and veins heat, scorchingly hot.For China, hide the common drug of the minority areas such as illiteracy.But the basic research of relevant wall tapestry is still very limited, the follow-up promotion and application of this medical material are restricted.Relevant wall tapestry chemical composition and pharmacological research have no report.
Domestic patent search result, has no wall tapestry Patents.
Above-mentioned document and patent etc., there is not yet wall tapestry or wall tapestry extract for the preparation of the report of medicines resistant to liver cancer.
Summary of the invention
The object of the present invention is to provide the application of wall tapestry extract in preparing medicines resistant to liver cancer.
The present invention is achieved through the following technical solutions:
The present invention's wall tapestry used is is the dry thallus of lichens Teloshistaceae plant wall tapestry Theloschestes flavicans (Sw.) Norm.
The application of wall tapestry extract of the present invention in preparing medicines resistant to liver cancer, the preparation method of described wall tapestry extract is:
(1) wall tapestry, adds 8-15 times of water, soaks 4-12 hour, adopts extraction by steam distillation volatile oil, extraction time 1-4 hour, and extraction time 1-3 time, collects volatile oil, obtains wall tapestry extract A; Wall tapestry aqueous extract is filtered, obtain respectively extracting solution A and medicinal residues A;
(2) step (1) being obtained to medicinal residues A is solvent with concentration 50%-95% ethanol, heating and refluxing extraction, and extraction time is 1-3 time, each extraction time is 1-3 hour, the 8-15 that each solvent load is wall tapestry weight doubly, filters, and extracting solution reclaims ethanol, concentrated, dry, obtain wall tapestry extract B;
(3) extracting solution A step (1) being obtained, is concentrated into relative density d=1.10-1.20, passes through macroporous adsorptive resins, first wash with water, then use the alcoholic solution eluting of concentration 50%-70%, collect different concentration ethanol eluent, concentrate drying, obtains wall tapestry extract C;
(4) above-mentioned wall tapestry extract A, wall tapestry extract B, wall tapestry extract C, wherein one or both or three kinds mix by a certain percentage, obtain wall tapestry extract of the present invention.
The preparation method of wall tapestry extract is:
(1) wall tapestry, adds 8-15 times of water, soaks 4-12 hour, adopts extraction by steam distillation volatile oil, extraction time 1-4 hour, and extraction time 1-3 time, collects volatile oil, obtains wall tapestry extract A; Wall tapestry aqueous extract is filtered, obtain respectively extracting solution A and medicinal residues A;
(2) step (1) being obtained to medicinal residues A is solvent with concentration 50%-95% ethanol, heating and refluxing extraction, and extraction time is 1-3 time, each extraction time is 1-3 hour, the 8-15 that each solvent load is wall tapestry weight doubly, filters, and extracting solution reclaims ethanol, concentrated, dry, obtain wall tapestry extract B;
(3) extracting solution A step (1) being obtained, is concentrated into relative density d=1.10-1.20, passes through macroporous adsorptive resins, first wash with water, then use the alcoholic solution eluting of concentration 50%-70%, collect different concentration ethanol eluent, concentrate drying, obtains wall tapestry extract C;
(4) above-mentioned wall tapestry extract A, wall tapestry extract B, wall tapestry extract C are mixed, obtain wall tapestry extract of the present invention.
The preparation method of preferred wall tapestry extract is:
(1) wall tapestry, adds 12 times of water, soaks 8 hours, adopts extraction by steam distillation volatile oil, and 2 hours extraction times, extraction time 2 times, collects volatile oil, obtains wall tapestry extract A; Wall tapestry aqueous extract is filtered, obtain respectively extracting solution A and medicinal residues A;
(2) step (1) being obtained to medicinal residues A is solvent with 70% ethanol, heating and refluxing extraction, and extraction time is 2 times, each extraction time is 2 hours, each solvent load is 12 times of wall tapestry weight, filters, and extracting solution reclaims ethanol, concentrated, dry, obtain wall tapestry extract B;
(3) extracting solution A step (1) being obtained, is concentrated into relative density d=1.15, by D101 macroporous adsorptive resins, first washes with water, then uses the alcoholic solution eluting of concentration 60%, collects 60% concentration ethanol eluent, and concentrate drying, obtains wall tapestry extract C;
(4) above-mentioned wall tapestry extract A, wall tapestry extract B, wall tapestry extract C are mixed, obtain wall tapestry extract of the present invention.
The preparation method of wall tapestry extract of the present invention, is characterized in that: the macroporous adsorbent resin adopting is D101 macroporous adsorbent resin, HPD600 macroporous adsorbent resin, DM130 macroporous adsorbent resin.
Wall tapestry extract of the present invention, by the various adjuvants that add pharmaceutics to allow, makes the peroral dosage forms such as tablet on pharmaceutics, granule, capsule.
Wall tapestry extract of the present invention and wall tapestry extract A, wall tapestry extract B, the application of wall tapestry extract C in preparing medicines resistant to liver cancer.
Wall tapestry extract of the present invention and chemical drugs or Chinese medicine or natural drug form medicines resistant to liver cancer.
Wall tapestry extract A of the present invention, wall tapestry extract B, wall tapestry extract C and chemical drugs or Chinese medicine or natural drug form medicines resistant to liver cancer.
The present invention adopts purification with macroreticular resin technology to wall tapestry first, and preparation has the extract of resisting liver cancer activity, and preparation technology is easy and simple to handle, and production cost is low, is suitable for industrialized great production.
The present invention's exploratory development first be take the dry thallus of lichens Teloshistaceae plant wall tapestry Theloschestes flavicans (Sw.) Norm and is that raw material extracts the anti-hepatocarcinoma extract of preparation.Pharmacological tests shows, each group of wall tapestry extract is compared gross tumor volume with model group and dwindled, and two weeks each treatment group tumor tissue of wall tapestry extract P53 of medication express significantly and decline; Macrophage CD
68testing result is shown: wall tapestry extract group and model control group comparison, have extremely significant difference (P<0.01).
The specific embodiment
Below by specific experiment example and embodiment, to wall tapestry extract, the application in preparing medicines resistant to liver cancer is described further, but is not limited to the present invention.
Embodiment 1: the preparation of wall tapestry extract
(1) wall tapestry 25kg, adds 12 times of water, soaks 8 hours, adopts extraction by steam distillation volatile oil, and 2 hours extraction times, extraction time 2 times, collects volatile oil, obtains wall tapestry extract A; Wall tapestry aqueous extract is filtered, obtain respectively extracting solution A and medicinal residues A;
(2) step (1) being obtained to medicinal residues A is solvent with concentration 70% ethanol, heating and refluxing extraction, and extraction time is 2 times, each extraction time is 2 hours, each solvent load is 12 times of wall tapestry weight, filters, and extracting solution reclaims ethanol, concentrated, dry, obtain wall tapestry extract B;
(3) extracting solution A step (1) being obtained, is concentrated into relative density d=1.15, by D101 macroporous adsorptive resins, first washes with water, then uses the alcoholic solution eluting of concentration 60%, collects 60% concentration ethanol eluent, and concentrate drying, obtains wall tapestry extract C;
(4) above-mentioned wall tapestry extract A, wall tapestry extract B and wall tapestry extract C are mixed, obtain wall tapestry extract of the present invention.
Embodiment 2: the preparation of wall tapestry extract
(1) wall tapestry, adds 15 times of water, soaks 4 hours, adopts extraction by steam distillation volatile oil, and 4 hours extraction times, extraction time 1 time, collects volatile oil, obtains wall tapestry extract A; Wall tapestry aqueous extract is filtered, obtain respectively extracting solution A and medicinal residues A;
(2) step (1) being obtained to medicinal residues A is solvent with 50% ethanol, heating and refluxing extraction, and extraction time is 1 time, each extraction time is 1 hour, each solvent load is 8 times of wall tapestry weight, filters, and extracting solution reclaims ethanol, concentrated, dry, obtain wall tapestry extract B;
(3) extracting solution A step (1) being obtained, is concentrated into relative density d=1.20, by HPD600 macroporous adsorptive resins, first wash with water, then use the alcoholic solution eluting of concentration 70%, collect 70% concentration ethanol eluent, concentrate drying, obtains wall tapestry extract C;
(4) above-mentioned wall tapestry extract A, wall tapestry extract B, wall tapestry extract C are mixed, obtain wall tapestry extract of the present invention.
Embodiment 3: the preparation of wall tapestry extract
(1) wall tapestry, adds 8 times of water, soaks 12 hours, adopts extraction by steam distillation volatile oil, and 1 hour extraction time, extraction time 3 times, collects volatile oil, obtains wall tapestry extract A; Wall tapestry aqueous extract is filtered, obtain respectively extracting solution A and medicinal residues A;
(2) step (1) being obtained to medicinal residues A is solvent with 95% ethanol, heating and refluxing extraction, and extraction time is 3 times, each extraction time is 3 hours, each solvent load is 15 times of wall tapestry weight, filters, and extracting solution reclaims ethanol, concentrated, dry, obtain wall tapestry extract B;
(3) extracting solution A step (1) being obtained, is concentrated into relative density d=1.10, by DM130 macroporous adsorptive resins, first wash with water, then use the alcoholic solution eluting of concentration 50%, collect 50% concentration ethanol eluent, concentrate drying, obtains wall tapestry extract C;
(4) above-mentioned wall tapestry extract A, wall tapestry extract B and wall tapestry extract C are mixed, obtain wall tapestry extract of the present invention.
Embodiment 4: the preparation of wall tapestry extract tablet
Get embodiment 2 wall tapestry extract 335g, add starch 110g, mix, granulate, dry, sieve, add microcrystalline Cellulose 48g, magnesium stearate 4.5g, mixes, and is pressed into 1000, obtains wall tapestry extract tablet.
Embodiment 5: the preparation of wall tapestry extract particles agent
Get embodiment 2 wall tapestry extract 240g, add dextrin 150g, mix, granulate, dry, granulate, obtains the agent of wall tapestry extract particles.
Embodiment 6: the preparation of wall tapestry extract capsule
Get embodiment 3 wall tapestry extract 305g, add starch 85g, mix, granulate, dry, sieve, add magnesium stearate 4g, mix, encapsulated 1000, obtain wall tapestry extract capsule.
Experimental example 1: the anti-hepatocarcinoma test of wall tapestry extract
1.1 material
Laboratory animal: 70 of healthy ICR mices, male, body weight 20 ± 2 g (Xi'an Jiaotong University Medical College's Experimental Animal Center provides), 28～30d.Credit number: SCXK (Shan) 2011-001.
Experiment tumor strain: mouse liver cell carcinoma strain (H
22) by university of The Fourth Military Medical University zoopery center, provide.
Medicine: by the embodiment of the present invention 1 method prepare wall tapestry extract, wall tapestry extract A, wall tapestry extract B, (lot number is respectively wall tapestry extract C: 20111011,20111012,20111013,20111014).Tegafur Tablet (FT-207), Shanghai Hua Lian pharmaceutical factory of Pharmaceutical Group company limited, the accurate word of traditional Chinese medicines: H31021668 lot number: 110905.
Main agents: P53 protein B A0133 multi-resistance, immunohistochemical staining test kit, Wuhan doctor's moral Bioisystech Co., Ltd provides.The anti-mouse macrophage polyclonal antibody of rabbit (SnataCurz, USA); CD
68immunohistochemical staining test kit, Wuhan doctor's moral Bioisystech Co., Ltd provides.Bioactivation element sheep anti-mouse igg BA0523,
DAB developer, SABC test kit, all purchased from Wuhan Boster Biological Technology Co., Ltd.; 0.02% trypan blue, PBS liquid 0.01m citric acid salt buffer, 95% ethanol, formaldehyde, dimethylbenzene, hydrogen peroxide, pure water provide by ShanXi Chinese Medicine Academy Pathological Staff Room.
Main experimental apparatus: superclean bench (Suzhou Decontamination Equipment Plant), cycle type histotome (2135 type Germany), optical microscope (optical instrument factory, Chongqing), electronic balance (Shanghai the second analytical tool factory), horizontal centrifuge (LD-42 type, Beijing Medical Centrifugal Machine Factory), electro-heating standing-temperature cultivator (Shanghai Medical Apparatus and Instruments Factory, HH Bll42), one of cryogenic refrigerator (Haier refrigerator factory, Qingdao), microscope slide, coverslip (the raw instrument of the sub-honorization in Shanghai), true color pathological image analytical system (Xiamen Mike Audi company), CCD photographing unit, Jiangsu Jetta morphological analysis software (EJDASOID), one of microwave oven (LG Electrical Appliances Co., Ltd), centrifuge tube, wet box etc.
1.2 experimental technique
The making of animal model: randomly draw 10 mices and do outside Normal group, make for all the other 40 and touch, rat liver cancer H
22the strain of hepatocarcinoma tumor tumor, extracts tumor liquid under aseptic condition, centrifugal (1500r/min * 2min) adjusts cell concentration to every milliliter of many 2 * 10m of suspension
2oncocyte, then uses 0.25mL syringe with 0.2mL/ only, the right armpit subcutaneous vaccination of mice, and it is 100% that the success rate of touching is made in this experiment.Experiment grouping and administration: after modeling, 24h, except normal blank group, is divided into 4 groups at random by mice, divide into groups to start gastric infusion the same day, and each organizes equal successive administration 14d: Normal group: with normal saline 0.2mL//d; Model control group: with normal saline 0.2mL//d; Ftorafur group: give 0.2mL//d; The aqueous solution that the Tegafur Tablet of 10 times of (containing ftorafur 4.0mg/mL) adult quantities is made; Wall tapestry extract, wall tapestry extract A, wall tapestry extract B, wall tapestry extract C, equal gavage, 0.2mL/, 1 time/d.
2 experimental results
2.1 tumor-inhibiting action
in Table 1.
Table 1 H
22the impact of liver cancer mouse tumor weight and tumour inhibiting rate
2.2 saltant type P53 and macrophage CD
68mensuration in Table 2.
Table 2 is respectively organized the expression of mutated P53 gene after administration
Note: with model control group comparison
△p<0.05,
▲p<0.01; With normal control comparison
◇p<0.01.
2.3 CD
68mensuration in Table 3.
Table 3 is respectively organized liver cancer mouse macrophage CD
68expression
Note: with model control group comparison
△p<0.05,
▲p<0.01; With normal control comparison
◇p<0.01.
This experiment detects H with Immunohistochemical Method
22the expression of hepatoma carcinoma cell mutant P 53 protein can be reacted the situation of P53 gene mutation.The overexpression of result display model group mice mutated P53 gene, is significantly higher than ftorafur positive controls and wall tapestry extract group, and the expression that wall tapestry extract can mutation inhibiting type P53 gene is described.Wall tapestry extract can make the expression of apoptosis suppressor saltant type P53 obviously reduce, show wall tapestry extract energy direct killing oncocyte, inhibition tumor cell propagation, liver cancer apoptosis reducing, its mechanism of action may be expressed and increase with antioncogene P53, can reduce the expression of hepatocarcinoma apoptosis suppressor saltant type P53, promote that apoptotic generation is relevant.
Wall tapestry extract group and the comparison of ftorafur group, both tumour inhibiting rates are that the former is not so good as the latter, but the latter has shown certain effectively tumour inhibiting rate; Wall tapestry extract of the present invention not only has certain tumor-inhibiting action and antineoplastic invasion and transfer, and can significantly improve the phagocytic function of macrophage.This is just in time consistent with " healthy energy deposit in, heresy can not be done " of the traditional Chinese medical science.
Claims (8)
1. the application of wall tapestry extract in preparing medicines resistant to liver cancer, the preparation method of described wall tapestry extract is:
(1) wall tapestry, adds 8-15 times of water, soaks 4-12 hour, adopts extraction by steam distillation volatile oil, extraction time 1-4 hour, and extraction time 1-3 time, collects volatile oil, obtains wall tapestry extract A; Wall tapestry aqueous extract is filtered, obtain respectively extracting solution A and medicinal residues A;
(2) step (1) being obtained to medicinal residues A is solvent with concentration 50%-95% ethanol, heating and refluxing extraction, and extraction time is 1-3 time, each extraction time is 1-3 hour, the 8-15 that each solvent load is wall tapestry weight doubly, filters, and extracting solution reclaims ethanol, concentrated, dry, obtain wall tapestry extract B;
(3) extracting solution A step (1) being obtained, is concentrated into relative density d=1.10-1.20, passes through macroporous adsorptive resins, first wash with water, then use the alcoholic solution eluting of concentration 50%-70%, collect different concentration ethanol eluent, concentrate drying, obtains wall tapestry extract C;
(4) above-mentioned wall tapestry extract A, wall tapestry extract B, wall tapestry extract C, wherein one or both or three kinds mix by a certain percentage, obtain wall tapestry extract of the present invention.
2. the preparation method of wall tapestry extract according to claim 1 is:
(1) wall tapestry, adds 8-15 times of water, soaks 4-12 hour, adopts extraction by steam distillation volatile oil, extraction time 1-4 hour, and extraction time 1-3 time, collects volatile oil, obtains wall tapestry extract A; Wall tapestry aqueous extract is filtered, obtain respectively extracting solution A and medicinal residues A;
(2) step (1) being obtained to medicinal residues A is solvent with concentration 50%-95% ethanol, heating and refluxing extraction, and extraction time is 1-3 time, each extraction time is 1-3 hour, the 8-15 that each solvent load is wall tapestry weight doubly, filters, and extracting solution reclaims ethanol, concentrated, dry, obtain wall tapestry extract B;
(3) extracting solution A step (1) being obtained, is concentrated into relative density d=1.10-1.20, passes through macroporous adsorptive resins, first wash with water, then use the alcoholic solution eluting of concentration 50%-70%, collect different concentration ethanol eluent, concentrate drying, obtains wall tapestry extract C;
(4) above-mentioned wall tapestry extract A, wall tapestry extract B, wall tapestry extract C are mixed, obtain wall tapestry extract of the present invention.
3. the preparation method of wall tapestry extract according to claim 1 is:
(1) wall tapestry, adds 12 times of water, soaks 8 hours, adopts extraction by steam distillation volatile oil, and 2 hours extraction times, extraction time 2 times, collects volatile oil, obtains wall tapestry extract A; Wall tapestry aqueous extract is filtered, obtain respectively extracting solution A and medicinal residues A;
(2) step (1) being obtained to medicinal residues A is solvent with 70% ethanol, heating and refluxing extraction, and extraction time is 2 times, each extraction time is 2 hours, each solvent load is 12 times of wall tapestry weight, filters, and extracting solution reclaims ethanol, concentrated, dry, obtain wall tapestry extract B;
(3) extracting solution A step (1) being obtained, is concentrated into relative density d=1.15, by D101 macroporous adsorptive resins, first washes with water, then uses the alcoholic solution eluting of concentration 60%, collects 60% concentration ethanol eluent, and concentrate drying, obtains wall tapestry extract C;
(4) above-mentioned wall tapestry extract A, wall tapestry extract B, wall tapestry extract C are mixed, obtain wall tapestry extract of the present invention.
4. according to the preparation method of claim 1, wall tapestry extract claimed in claim 2, it is characterized in that: the macroporous adsorbent resin adopting is D101 macroporous adsorbent resin, HPD600 macroporous adsorbent resin, DM130 macroporous adsorbent resin.
5. according to claim 1, claim 2, wall tapestry extract claimed in claim 3, by the various adjuvants that add pharmaceutics to allow, make the peroral dosage forms such as tablet on pharmaceutics, granule, capsule.
6. wall tapestry extract A according to claim 1, wall tapestry extract B, wall tapestry extract C, the application in preparing medicines resistant to liver cancer.
7. wall tapestry extract A according to claim 1, wall tapestry extract B, wall tapestry extract C and chemical drugs or Chinese medicine or natural drug form medicines resistant to liver cancer.
8. wall tapestry extract according to claim 1 and chemical drugs or Chinese medicine or natural drug form medicines resistant to liver cancer.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310525674.9A CN103585190B (en) | 2013-10-31 | 2013-10-31 | Wall tapestry extract is preparing the application in medicines resistant to liver cancer |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310525674.9A CN103585190B (en) | 2013-10-31 | 2013-10-31 | Wall tapestry extract is preparing the application in medicines resistant to liver cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103585190A true CN103585190A (en) | 2014-02-19 |
| CN103585190B CN103585190B (en) | 2015-10-28 |
Family
ID=50075644
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310525674.9A Expired - Fee Related CN103585190B (en) | 2013-10-31 | 2013-10-31 | Wall tapestry extract is preparing the application in medicines resistant to liver cancer |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103585190B (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1698769A (en) * | 2005-05-17 | 2005-11-23 | 重庆医药工业研究院有限责任公司 | Bupleurum root soft capsule and its preparation method |
| CN102671017A (en) * | 2012-04-27 | 2012-09-19 | 湖北长友现代农业股份有限公司 | Method for simultaneously preparing indocalamus leaf volatile oil, total flavone and total polysaccharide |
-
2013
- 2013-10-31 CN CN201310525674.9A patent/CN103585190B/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1698769A (en) * | 2005-05-17 | 2005-11-23 | 重庆医药工业研究院有限责任公司 | Bupleurum root soft capsule and its preparation method |
| CN102671017A (en) * | 2012-04-27 | 2012-09-19 | 湖北长友现代农业股份有限公司 | Method for simultaneously preparing indocalamus leaf volatile oil, total flavone and total polysaccharide |
Non-Patent Citations (3)
| Title |
|---|
| YOSHIKAZU YAMAMOTO: ""Lichen-derived Culture and Its Pharmaceutical Applications"", 《INTERNATIONAL SYMPOSIUM ON SYSTEMATIC LICHENOLOGY BRYOLOGY》 * |
| 张璞 等: ""地衣抗生素和地衣多糖类物质的研究进展"", 《山东科学》 * |
| 房敏峰 等: ""地衣化学成分和药理作用研究进展"", 《中草药》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103585190B (en) | 2015-10-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Wang et al. | Immuno-enhancement effects of Shenqi Fuzheng Injection on cyclophosphamide-induced immunosuppression in Balb/c mice | |
| CN106236801A (en) | Pseudo-ginseng activity medicine that super-micro wall-broken crushing technology is made and health product and preparation method thereof | |
| CN103405487B (en) | Chinese medicine compound effective part with effect of treating arthritis | |
| CN103585209B (en) | Dorema ammoniacum resin extract is preparing the application in medicines resistant to liver cancer | |
| Zhou et al. | Immunomodulatory and antioxidant effects of Glycyrrhiza uralensis polysaccharide in Lohmann Brown chickens | |
| Liang et al. | Effect of Chinese herbal compound on liver fibrosis in rabbits with schistosomiasis by B-ultrasound | |
| CN103655590A (en) | Pharmaceutical composition containing gentiopicroside and preparation and usage thereof | |
| CN103585190B (en) | Wall tapestry extract is preparing the application in medicines resistant to liver cancer | |
| CN102772554A (en) | Traditional Chinese medicine compound for curing schizophrenia | |
| CN102018747B (en) | Application of red stilbene and red stilbene polysaccharide in preparing medicament for improvement of learning memory and treatment of Alzheimer disease | |
| CN101904894B (en) | Application of lamiophlomis rotate total glycosides in preparing medicines | |
| CN102935131B (en) | Application of Fructus Aurantii Immaturus total flavonoid extract in preparation of drug treating bronchial asthma | |
| CN104688723A (en) | Application of anhydroicaritin in preparation of medicine for treating anaemia | |
| CN104473936A (en) | Pharmaceutical composition used for treating liver cancer | |
| CN104523726A (en) | Pharmaceutical composition for treating liver cancer | |
| CN104473949A (en) | Pharmaceutical composition used for treating liver cancer | |
| CN104510749A (en) | Pharmaceutical composition for treating liver cancer | |
| CN101816702B (en) | Lung cancer preventing and treating composition extracted from selfheal and/or garden orache and application thereof in preparation of lung cancer preventing and treating medicine | |
| CN102362993B (en) | Chinese medicinal preparation with effects of protecting intestines and removing toxic materials, and preparation method thereof | |
| CN101926929A (en) | Traditional Chinese medicine for treating vascular dementia and preparation method thereof | |
| CN105012413A (en) | Traditional Chinese medicinal composition with the effect of lowering blood fat, and preparation method and application thereof | |
| CN104523704A (en) | Pharmaceutical composition for treating liver cancer | |
| Cheng et al. | Cynanchum paniculatum (Bunge) Kitag. ex H. Hara inhibits pancreatic cancer progression by inducing caspase-dependent apoptosis and suppressing TGF-β-mediated epithelial-mesenchymal transition | |
| CN102688296B (en) | Chinese medicine composition with effect of reducing blood fat as well as preparation method and application thereof | |
| CN103961428B (en) | A kind of detection method of the Chinese medicinal composition preparation with promoting flow of QI and blood effect |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| ASS | Succession or assignment of patent right |
Owner name: YU SHUJUAN Free format text: FORMER OWNER: JINAN XINGYI MEDICAL TECHNOLOGY CO., LTD. Effective date: 20150907 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| C53 | Correction of patent of invention or patent application | ||
| CB03 | Change of inventor or designer information |
Inventor after: Yu Shujuan Inventor before: Kong Qianqian |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: KONG QIANQIAN TO: YU SHUJUAN |
|
| TA01 | Transfer of patent application right |
Effective date of registration: 20150907 Address after: 265100 No. 5, building 21, building 36, No. 401, Hai Dao Road, Haiyang, Shandong, Yantai Applicant after: Yu Shujuan Address before: 250101 No. 51 Industrial South Road, Ji'nan hi tech Zone, Shandong, Ji'nan Applicant before: Jinan Xingyi Medical Technology Co.,Ltd. |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20151028 Termination date: 20161031 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |